Breakthrough in Cancer Immunotherapy: Overcoming Steroid Resistance
The Hidden Barrier in Tumours
Recent research published in Signal Transduction and Targeted Therapy reveals a critical obstacle in cancer treatment: the tumour microenvironment itself. Lung tumours are enriched with glucocorticoids—particularly cortisol—which suppress the body’s immune response. These steroids weaken natural killer (NK) cells, a key component of the immune system responsible for destroying cancer cells, reducing their ability to attack tumours effectively.
How Cortisol Disarms Immune
The study shows that cortisol reprograms NK cells at a genetic level, dampening their cytotoxic activity while increasing cellular stress linked to hypoxia (low oxygen conditions). This creates a hostile environment where immune cells become dysfunctional. Importantly, multiple cell types within tumours actively contribute to this steroid-rich environment, amplifying immune suppression and enabling tumour survival.
Engineering a Smarter Immune Response
To counter this challenge, researchers developed a novel approach: cortisol-resistant CAR-NK cells. These are genetically engineered immune cells designed to target cancer while remaining unaffected by cortisol. By removing the glucocorticoid receptor (NR3C1), scientists prevented cortisol from interfering with NK cell function.
The results are promising. These modified cells maintained their tumour-killing ability even in steroid-rich conditions and showed significantly improved anti-cancer activity in preclinical models.
Why This Matters
This discovery highlights cortisol as a previously underappreciated barrier to effective immunotherapy. By addressing steroid-induced immune suppression, this approach could enhance the success of treatments for lung cancer and potentially other solid tumours.
Looking Ahead
Cortisol-resistant CAR-NK therapy represents a new frontier in cancer treatment—one that not only targets tumours directly but also neutralises the environment that protects them. As research progresses, this strategy may pave the way for more resilient and effective immunotherapies.